Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February...